已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Carfilzomib公司 医学 多发性骨髓瘤 内科学 地塞米松 人口 肿瘤科 来那度胺 环境卫生
作者
Philippe Moreau,Meletios Athanasios Dimopoulos,Joseph R Mikhael,Kwee Yong,Marcelo Capra,Thierry T.F. Facon,Roman Hájek,Ivan Špıčka,Ross Ian Baker,Kihyun Kım,Gracia Martınez,Chang‐Ki Min,Luděk Pour,Xavier P Leleu,Albert Oriol,Youngil Koh,Kenshi Suzuki,Marie‐Laure Risse,Gaëlle Asset,Sandrine Macé
出处
期刊:The Lancet [Elsevier BV]
卷期号:397 (10292): 2361-2371 被引量:416
标识
DOI:10.1016/s0140-6736(21)00592-4
摘要

Isatuximab is an anti-CD38 monoclonal antibody approved in combination with pomalidomide-dexamethasone and carfilzomib-dexamethasone for relapsed or refractory multiple myeloma. This phase 3, open-label study compared the efficacy of isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma.This was a prospective, randomised, open-label, parallel-group, phase 3 study done at 69 study centres in 16 countries across North America, South America, Europe, and the Asia-Pacific region. Patients with relapsed or refractory multiple myeloma aged at least 18 years who had received one to three previous lines of therapy and had measurable serum or urine M-protein were eligible. Patients were randomly assigned (3:2) to isatuximab plus carfilzomib-dexamethasone (isatuximab group) or carfilzomib-dexamethasone (control group). Patients in the isatuximab group received isatuximab 10 mg/kg intravenously weekly for the first 4 weeks, then every 2 weeks. Both groups received the approved schedule of intravenous carfilzomib and oral or intravenous dexamethasone. Treatment continued until progression or unacceptable toxicity. The primary endpoint was progression-free survival and was assessed in the intention-to-treat population according to assigned treatment. Safety was assessed in all patients who received at least one dose according to treatment received. The study is registered at ClinicalTrials.gov, NCT03275285.Between Nov 15, 2017, and March 21, 2019, 302 patients with a median of two previous lines of therapy were enrolled. 179 were randomly assigned to the isatuximab group and 123 to the control group. Median progression-free survival was not reached in the isatuximab group compared with 19·15 months (95% CI 15·77-not reached) in the control group, with a hazard ratio of 0·53 (99% CI 0·32-0·89; one-sided p=0·0007). Treatment-emergent adverse events (TEAEs) of grade 3 or worse occurred in 136 (77%) of 177 patients in the isatuximab group versus 82 (67%) of 122 in the control group, serious TEAEs occurred in 105 (59%) versus 70 (57%) patients, and TEAEs led to discontinuation in 15 (8%) versus 17 (14%) patients. Fatal TEAEs during study treatment occurred in six (3%) versus four (3%) patients.The addition of isatuximab to carfilzomib-dexamethasone significantly improves progression-free survival and depth of response in patients with relapsed multiple myeloma, representing a new standard of care for this patient population.Sanofi. VIDEO ABSTRACT.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
赘婿的应助被给我嘉晚饭采纳,获得10
刚刚
刚刚
1秒前
SixyHao发布了新的文献求助10
1秒前
斯文败类的应助被wzj采纳,获得10
1秒前
甜蜜鹭洋完成签到,获得积分10
1秒前
搜集达人的应助被孙朱珠采纳,获得10
2秒前
纯情的阁的应助被mmmm采纳,获得210
2秒前
桐桐的应助被努力做颗盐采纳,获得10
3秒前
清脆如风完成签到 ,获得积分10
4秒前
酷波er的应助被道友且慢采纳,获得20
5秒前
悍劲芭比单挑孔子完成签到 ,获得积分10
5秒前
6秒前
nangua完成签到,获得积分10
6秒前
小二郎的应助被魔术师霸霸采纳,获得10
7秒前
gggk完成签到,获得积分20
7秒前
8秒前
8秒前
qianza发布了新的文献求助10
9秒前
vanilla完成签到,获得积分10
10秒前
11秒前
极限001给mahuahua的求助进行了留言
12秒前
Gjorv完成签到 ,获得积分10
12秒前
smile完成签到,获得积分10
12秒前
13秒前
14秒前
a553355完成签到,获得积分10
15秒前
斯文败类的应助被密密麻麻的采纳,获得10
15秒前
慕青的应助被还读书呢采纳,获得20
15秒前
kiteshowbbs发布了新的文献求助10
15秒前
地球翻转完成签到 ,获得积分10
16秒前
共享精神的应助被盈虚者采纳,获得10
16秒前
我是老大的应助被Zoe采纳,获得10
17秒前
17秒前
星辰大海的应助被fortuna采纳,获得10
18秒前
李爱国的应助被mt采纳,获得10
18秒前
19秒前
19秒前
haha发布了新的文献求助10
19秒前
爆米花的应助被期盼花开吗采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158064
求助须知:如何正确求助?哪些是违规求助? 9553987
关于积分的说明 21716926
捐赠科研通 7747422
什么是DOI,文献DOI怎么找? 3426934
关于科研通互助平台的介绍 2551676
邀请新用户注册赠送积分活动 2471057